These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10306 related articles for article (PubMed ID: 15715049)
1. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. Gyorffy S; Rodriguez-Lecompte JC; Woods JP; Foley R; Kruth S; Liaw PC; Gauldie J J Vet Intern Med; 2005; 19(1):56-63. PubMed ID: 15715049 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218 [TBL] [Abstract][Full Text] [Related]
3. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL. Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015 [TBL] [Abstract][Full Text] [Related]
4. Generation of blood-derived dendritic cells in dogs with oral malignant melanoma. Catchpole B; Stell AJ; Dobson JM J Comp Pathol; 2002; 126(2-3):238-41. PubMed ID: 11945016 [TBL] [Abstract][Full Text] [Related]
6. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759 [TBL] [Abstract][Full Text] [Related]
7. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127 [TBL] [Abstract][Full Text] [Related]
8. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
9. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma. Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736 [TBL] [Abstract][Full Text] [Related]
10. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823 [TBL] [Abstract][Full Text] [Related]
11. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286 [TBL] [Abstract][Full Text] [Related]
12. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017 [TBL] [Abstract][Full Text] [Related]
13. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986 [TBL] [Abstract][Full Text] [Related]
14. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766 [TBL] [Abstract][Full Text] [Related]
16. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296 [TBL] [Abstract][Full Text] [Related]
17. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Alexander AN; Huelsmeyer MK; Mitzey A; Dubielzig RR; Kurzman ID; Macewen EG; Vail DM Cancer Immunol Immunother; 2006 Apr; 55(4):433-42. PubMed ID: 15965647 [TBL] [Abstract][Full Text] [Related]
18. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
19. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257 [TBL] [Abstract][Full Text] [Related]
20. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. Lotem M; Zhao Y; Riley J; Hwu P; Morgan RA; Rosenberg SA; Parkhurst MR J Immunother; 2006; 29(6):616-27. PubMed ID: 17063124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]